

Are the psychoto-mimetic effects of cannabis mediated via dopamine?

Submission date 28/09/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 28/09/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 14/10/2014	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof - -

Contact details
Institute of Nuclear Medicine
University College Hospital
5th Floor
235 Euston Road
London
United Kingdom
NW1 2BU

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0263181140

Study information

Scientific Title

Study objectives

Are the transient psychotic like effects induced by delta-9-tetrahydrocannabinol correlated with excess dopamine release in the striatum as measures by (123I)-IBZM single photon emission tomography (SPET)?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Mental and Behavioural Disorders: Psychosis

Interventions

1. THC drug
2. Placebo

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Cannabis

Primary outcome measure

1. The percentage decrease in specific (123I)-IBZM binding under THC vs placebo conditions
2. The relationship between THC induced PANSS increases and (123I)-IBZM displacement

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/06/2006

Completion date

01/12/2007

Eligibility

Key inclusion criteria

External patients

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/06/2006

Date of final enrolment

01/12/2007

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Institute of Nuclear Medicine

London

United Kingdom
NW1 2BU

Sponsor information

Organisation

Record Provided by the NHSTCT Register - 2007 Update - Department of Health

Sponsor details

The Department of Health, Richmond House, 79 Whitehall
London
United Kingdom
SW1A 2NL
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type

Government

Funder Name

University College London Hospitals NHS Foundation Trust (UK)

Funder Name

NHS R&D Support Funding (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration